Annika Blank

Annika Blank

Auto-generated profile, based on publicly available information

Annika Blank

F. Hoffmann-La Roche AG, Pharmaceutical Research and Early Development Oncology, Roche Innovation Center Zurich, Zurich, Switzerland

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
DDDavid Dejardin
David Dejardin
AKAnton Kraxner
Anton Kraxner
ABAnnika Blank
Annika Blank
NRNatascha Rieder
Natascha Rieder
VTVolker Teichgräber
Volker Teichgräber
JCJehad Charo
Jehad Charo
Purpose: To examine whether CD8+ T-cell numbers in paired tumor biopsies in early-stage clinical trials can be used as an early indicator of clinical benefit for cancer immunotherapies. Experimental Design: Paraffin sections of tumor biopsies were stained immunohistochemically for CD8+ T cells, which were digitally enumerated. The tumor biopsies were from cancer patients in early-phase trials testing novel immunotherapeutic agents. Paired biopsies taken before the start of treatment and on-treatment were compared. A total of 155 patients were used as the training set and an additional 221 patients were used as the validation set. Results: Using the Cox proportional hazard model, a ≥0.9- increase in fold change (FC) on a ln scale in CD8+ T cells (corresponding to a 2.5-fold increase on the linear scale), from baseline, demonstrated a greater association with prolonged progression-free survival and allowed improved differentiation between groups above and below the threshold. Similarly, a ≥6.2 threshold in geometric mean of the on-treatment density (OTD) of T cells, which approximately corresponds to 500 cells/mm2, correlated with longer PFS. The combination of both criteria (FC and OTD) provided the best discrimination between clinically nonactive and active compounds. Conclusions: We propose that a composite score of CD8+ T-cell density in paired biopsies taken before and on-treatment may be a new biomarker to inform on clinical outcomes in early immunotherapy clinical trials.

16 February 2024
Verified
Other
Open access
PDF file
DDDavid Dejardin
David Dejardin
AKAnton Kraxner
Anton Kraxner
ABAnnika Blank
Annika Blank
NRNatascha Rieder
Natascha Rieder
VTVolker Teichgräber
Volker Teichgräber
JCJehad Charo
Jehad Charo
Higher response rate in groups above CD8 density threshold.

16 February 2024
Verified
Other
Open access
PDF file
DDDavid Dejardin
David Dejardin
AKAnton Kraxner
Anton Kraxner
ABAnnika Blank
Annika Blank
NRNatascha Rieder
Natascha Rieder
VTVolker Teichgräber
Volker Teichgräber
JCJehad Charo
Jehad Charo
Baseline density distribution in the cohorts reported with decision rule.

16 February 2024
Verified
Other
Open access
PDF file
DDDavid Dejardin
David Dejardin
AKAnton Kraxner
Anton Kraxner
ABAnnika Blank
Annika Blank
NRNatascha Rieder
Natascha Rieder
VTVolker Teichgräber
Volker Teichgräber
JCJehad Charo
Jehad Charo
Higher total CD8 T cell density is associated with better response in simlukafusp alfa studies.

16 February 2024
Verified
Other
Open access
DDDavid Dejardin
David Dejardin
AKAnton Kraxner
Anton Kraxner
ABAnnika Blank
Annika Blank
NRNatascha Rieder
Natascha Rieder
VTVolker Teichgräber
Volker Teichgräber
JCJehad Charo
Jehad Charo
Purpose:To examine whether CD8+ T-cell numbers in paired tumor biopsies in early-stage clinical trials can be used as an early indicator of clinical benefit for cancer immunotherapies.Experimental Design:Paraffin sections of tumor biopsies were stained immunohistochemically for CD8+ T cells, which were digitally enumerated. The tumor biopsies were from cancer patients in early-phase trials testing novel immunotherapeutic agents. Paired biopsies taken before the start of treatment and on-treatment were compared. A total of 155 patients were used as the training set and an additional 221 patients were used as the validation set.Results:Using the Cox proportional hazard model, a ≥0.9- increase in fold change (FC) on a ln scale in CD8+ T cells (corresponding to a 2.5-fold increase on the linear scale), from baseline, demonstrated a greater association with prolonged progression-free survival and allowed improved differentiation between groups above and below the threshold. Similarly, a ≥6.2 threshold in geometric mean of the on-treatment density (OTD) of T cells, which approximately corresponds to 500 cells/mm2, correlated with longer PFS. The combination of both criteria (FC and OTD) provided the best discrimination between clinically nonactive and active compounds.Conclusions:We propose that a composite score of CD8+ T-cell density in paired biopsies taken before and on-treatment may be a new biomarker to inform on clinical outcomes in early immunotherapy clinical trials.

16 February 2024
Verified
Other
Open access
PDF file
DDDavid Dejardin
David Dejardin
AKAnton Kraxner
Anton Kraxner
ABAnnika Blank
Annika Blank
NRNatascha Rieder
Natascha Rieder
VTVolker Teichgräber
Volker Teichgräber
JCJehad Charo
Jehad Charo
Higher response rate in groups above CD8 density threshold.